docetaxel anhydrous has been researched along with 5-(n,n-hexamethylene)amiloride in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (5-(n,n-hexamethylene)amiloride) | Trials (5-(n,n-hexamethylene)amiloride) | Recent Studies (post-2010) (5-(n,n-hexamethylene)amiloride) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 145 | 0 | 34 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | 5-(n,n-hexamethylene)amiloride (IC50) |
|---|---|---|---|
| Urokinase-type plasminogen activator | Homo sapiens (human) | 2.4 | |
| Adenosine receptor A2a | Homo sapiens (human) | 2.685 | |
| Adenosine receptor A2b | Homo sapiens (human) | 0.27 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berg, AL; Carraway, KL; Curiel, DA; Hatakeyama, J; Leon, LJ; Rowson-Hodel, AR; Sweeney, C; VanderVorst, K; Wald, JH | 1 |
1 other study(ies) available for docetaxel anhydrous and 5-(n,n-hexamethylene)amiloride
| Article | Year |
|---|---|
Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
Topics: Amiloride; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Lysosomes; Necrosis; Reactive Oxygen Species; Taxoids | 2016 |